Roberto Scicali

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5757007/publications.pdf

Version: 2024-02-01

95 papers

2,323 citations

212478 28 h-index 299063 42 g-index

98 all docs 98 docs citations 98 times ranked 3808 citing authors

#	Article	IF	CITATIONS
1	Associations of pro-protein convertase subtilisin-like kexin type 9, soluble low-density lipoprotein receptor and coronary artery disease. International Journal of Cardiology, 2022, , .	0.8	О
2	Influence of Body Mass Index, Cancer Type and Treatment on Long-Term Metabolic and Liver Outcomes in Childhood Cancer Survivors. Journal of Clinical Medicine, 2022, 11, 878.	1.0	2
3	Analysis of gingival crevicular fluid biomarkers in patients with metabolic syndrome. Journal of Dentistry, 2022, 118, 104065.	1.7	2
4	Achilles tendon ultrasonography in familial hypercholesterolemia: A subâ€study of the Llpid transPort disorders Italian GEnetic Network (LIPIGEN). Journal of Internal Medicine, 2022, 291, 702-704.	2.7	2
5	PCSK9 Plasma Levels Are Associated with Mechanical Vascular Impairment in Familial Hypercholesterolemia Subjects without a History of Atherosclerotic Cardiovascular Disease: Results of Six-Month Add-On PCSK9 Inhibitor Therapy. Biomolecules, 2022, 12, 562.	1.8	11
6	The impact of obesity and dyslipidemia on Remdesivir effectiveness in hospitalized patients with SARS-CoV-2-related pneumonia: An observational study. Nutrition, Metabolism and Cardiovascular Diseases, 2022, 32, 1635-1641.	1.1	2
7	Increased Platelet Reactivity and Proinflammatory Profile Are Associated with Intima–Media Thickness and Arterial Stiffness in Prediabetes. Journal of Clinical Medicine, 2022, 11, 2870.	1.0	3
8	Emerging Circulating Biomarkers in Atherosclerosis: From Molecular Mechanisms to Therapeutic Strategies. Biomolecules, 2022, 12, 809.	1.8	0
9	Molecular Effects of Chronic Exposure to Palmitate in Intestinal Organoids: A New Model to Study Obesity and Diabetes. International Journal of Molecular Sciences, 2022, 23, 7751.	1.8	2
10	Effects of Lipid Lowering Therapy Optimization by PCSK9 Inhibitors on Circulating CD34+ Cells and Pulse Wave Velocity in Familial Hypercholesterolemia Subjects without Atherosclerotic Cardiovascular Disease: Real-World Data from Two Lipid Units. Biomedicines, 2022, 10, 1715.	1.4	4
11	Comparative effectiveness of dapagliflozin vs <scp>DPP</scp> â€4 inhibitors on a composite endpoint of <scp>HbA1c</scp> , body weight and blood pressure reduction in the real world. Diabetes/Metabolism Research and Reviews, 2021, 37, e3353.	1.7	17
12	High <scp>TG</scp> to <scp>HDL</scp> ratio plays a significant role on atherosclerosis extension in prediabetes and newly diagnosed type 2 diabetes subjects. Diabetes/Metabolism Research and Reviews, 2021, 37, e3367.	1.7	44
13	Effect of PCSK9 inhibitors on pulse wave velocity and monocyte-to-HDL-cholesterol ratio in familial hypercholesterolemia subjects: results from a single-lipid-unit real-life setting. Acta Diabetologica, 2021, 58, 949-957.	1.2	15
14	Analysis of steatosis biomarkers and inflammatory profile after adding on PCSK9 inhibitor treatment in familial hypercholesterolemia subjects with nonalcoholic fatty liver disease: A single lipid center real-world experience. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 869-879.	1,1	26
15	Bone fragility in patients with diabetes mellitus: A consensus statement from the working group of the Italian Diabetes Society (SID), Italian Society of Endocrinology (SIE), Italian Society of Gerontology and Geriatrics (SIGG), Italian Society of Orthopaedics and Traumatology (SIOT). Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1375-1390.	1.1	8
16	Cardiovascular risk management in type 2 diabetes mellitus: A joint position paper of the Italian Cardiology (SIC) and Italian Diabetes (SID) Societies. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 1671-1690.	1.1	5
17	High Glucose Exposure Impairs L-Cell Differentiation in Intestinal Organoids: Molecular Mechanisms and Clinical Implications. International Journal of Molecular Sciences, 2021, 22, 6660.	1.8	17
18	Proprotein Convertase Subtilisin Kexin Type 9 Inhibitors Reduce Platelet Activation Modulating ox-LDL Pathways. International Journal of Molecular Sciences, 2021, 22, 7193.	1.8	26

#	Article	IF	Citations
19	Beneficial effects of glucagon-like peptide 1 receptor agonists on glucose control, cardiovascular risk profile, and non-alcoholic fatty liver disease. An expert opinion of the Italian diabetes society. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3257-3270.	1.1	7
20	Glucagon as a Therapeutic Approach to Severe Hypoglycemia: After 100 Years, Is It Still the Antidote of Insulin?. Biomolecules, 2021, 11, 1281.	1.8	5
21	High glomerular filtration rate is associated with impaired arterial stiffness and subendocardial viability ratio in prediabetic subjects. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3393-3400.	1.1	11
22	Coffee Restores Expression of IncRNAs Involved in Steatosis and Fibrosis in a Mouse Model of NAFLD. Nutrients, 2021, 13, 2952.	1.7	19
23	Impact of high neutrophil-to-lymphocyte ratio on the cardiovascular benefit of PCSK9 inhibitors in familial hypercholesterolemia subjects with atherosclerotic cardiovascular disease: Real-world data from two lipid units. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 3401-3406.	1.1	10
24	Direct and Indirect Effects of SARS-CoV-2 Pandemic in Subjects with Familial Hypercholesterolemia: A Single Lipid-Center Real-World Evaluation. Journal of Clinical Medicine, 2021, 10, 4363.	1.0	5
25	Clinical and Molecular Biomarkers for Diagnosis and Staging of NAFLD. International Journal of Molecular Sciences, 2021, 22, 11905.	1.8	34
26	Direct Effects of D-Chiro-Inositol on Insulin Signaling and Glucagon Secretion of Pancreatic Alpha Cells. Biomolecules, 2020, 10, 1404.	1.8	11
27	Management of type 2 diabetes for prevention of cardiovascular disease. An expert opinion of the Italian Diabetes Society. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1926-1936.	1.1	7
28	Author's reply to: Arterial stiffness improvement after adding on PCSK9 inhibitors in patients with familial hypercholesterolemia, a letter from Papaioannou and colleagues. Journal of Clinical Lipidology, 2020, 14, 543.	0.6	1
29	Circulating Coding and Long Non-Coding RNAs as Potential Biomarkers of Idiopathic Pulmonary Fibrosis. International Journal of Molecular Sciences, 2020, 21, 8812.	1.8	21
30	Analysis of Arterial Stiffness and Sexual Function after Adding on PCSK9 Inhibitor Treatment in Male Patients with Familial Hypercholesterolemia: A Single Lipid Center Real-World Experience. Journal of Clinical Medicine, 2020, 9, 3597.	1.0	10
31	May statins and PCSK9 inhibitors be protective from COVID-19 in familial hypercholesterolemia subjects?. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1068-1069.	1.1	20
32	Italian recommendations for the diagnosis of gestational diabetes during COVID-19 pandemic: Position statement of the Italian Association of Clinical Diabetologists (AMD) and the Italian Diabetes Society (SID), diabetes, and pregnancy study group. Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1418-1422.	1.1	17
33	Diabetic ketoacidosis: A consensus statement of the Italian Association of Medical Diabetologists (AMD), Italian Society of Diabetology (SID), Italian Society of Endocrinology and Pediatric Diabetoloy (SIEDP). Nutrition, Metabolism and Cardiovascular Diseases, 2020, 30, 1633-1644.	1.1	16
34	Arterial stiffness improvement after adding on PCSK9 inhibitors or ezetimibe to high-intensity statins in patients with familial hypercholesterolemia: A Two–Lipid Center Real-World Experience. Journal of Clinical Lipidology, 2020, 14, 231-240.	0.6	35
35	The entero-insular axis: a journey in the physiopathology of diabetes. Exploration of Medicine, 2020, $1, \dots$	1.5	1
36	Guidelines for the screening and diagnosis of gestational diabetes in Italy from 2010 to 2019: critical issues and the potential for improvement. Acta Diabetologica, 2019, 56, 1159-1167.	1.2	10

#	Article	IF	Citations
37	1 h Postload Glycemia Is Associated with Low Endogenous Secretory Receptor for Advanced Glycation End Product Levels and Early Markers of Cardiovascular Disease. Cells, 2019, 8, 910.	1.8	27
38	Serum coding and nonâ€coding RNAs as biomarkers of NAFLD and fibrosis severity. Liver International, 2019, 39, 1742-1754.	1.9	51
39	Pathophysiological, Molecular and Therapeutic Issues of Nonalcoholic Fatty Liver Disease: An Overview. International Journal of Molecular Sciences, 2019, 20, 1948.	1.8	127
40	Analysis of S100A12 plasma levels in hyperlipidemic subjects with or without familial hypercholesterolemia. Acta Diabetologica, 2019, 56, 899-906.	1.2	13
41	Analysis of HDL-microRNA panel in heterozygous familial hypercholesterolemia subjects with LDL receptor null or defective mutation. Scientific Reports, 2019, 9, 20354.	1.6	21
42	Ten years of experience with DPP-4 inhibitors for the treatment of type 2 diabetes mellitus. Acta Diabetologica, 2019, 56, 605-617.	1.2	50
43	Left ventricular geometry and periodontitis in patients with the metabolic syndrome. Clinical Oral Investigations, 2019, 23, 2695-2703.	1.4	13
44	Impaired glucagon suppression and reduced insulin sensitivity in subjects with prediabetes undergoing atorvastatin therapy. European Journal of Endocrinology, 2019, 181, 579-590.	1.9	6
45	2218-PUB: Increased Platelet Reactivity Is Associated with Inflammation and Arterial Stiffness in Subjects with Prediabetes. Diabetes, 2019, 68, 2218-PUB.	0.3	0
46	An increased waist-to-hip ratio is a key determinant of atherosclerotic burden in overweight subjects. Acta Diabetologica, 2018, 55, 741-749.	1.2	30
47	Platelet Count Does Not Predict Bleeding in Cirrhotic Patients: Results from the PRO-LIVER Study. American Journal of Gastroenterology, 2018, 113, 368-375.	0.2	82
48	New treatment options for lipid-lowering therapy in subjects with type 2 diabetes. Acta Diabetologica, 2018, 55, 209-218.	1.2	32
49	Major adverse cardiovascular events in non-valvular atrial fibrillation with chronic obstructive pulmonary disease: the ARAPACIS study. Internal and Emergency Medicine, 2018, 13, 651-660.	1.0	29
50	Detecting familial hypercholesterolemia by serum lipid profile screening in a hospital setting: Clinical, genetic and atherosclerotic burden profile. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 35-43.	1.1	22
51	Abnormalities of Lipoprotein Levels in Liver Cirrhosis: Clinical Relevance. Digestive Diseases and Sciences, 2018, 63, 16-26.	1.1	33
52	Chronic Exposure to Palmitate Impairs Insulin Signaling in an Intestinal L-cell Line: A Possible Shift from GLP-1 to Glucagon Production. International Journal of Molecular Sciences, 2018, 19, 3791.	1.8	26
53	Evaluation of the performance of Dutch Lipid Clinic Network score in an Italian FH population: The LIPIGEN study. Atherosclerosis, 2018, 277, 413-418.	0.4	48
54	Inflammation and ventricular-vascular coupling in hypertensive patients with metabolic syndrome. Nutrition, Metabolism and Cardiovascular Diseases, 2018, 28, 1222-1229.	1.1	11

#	Article	IF	Citations
55	Impact of Western and Mediterranean Diets and Vitamin D on Muscle Fibers of Sedentary Rats. Nutrients, 2018, 10, 231.	1.7	28
56	Early effects of high-fat diet, extra-virgin olive oil and vitamin D in a sedentary rat model of non-alcoholic fatty liver disease. Histology and Histopathology, 2018, 33, 1201-1213.	0.5	13
57	Carotid plaque detection improves the predictive value of CHA2DS2-VASc score in patients with non-valvular atrial fibrillation: The ARAPACIS Study. International Journal of Cardiology, 2017, 231, 143-149.	0.8	22
58	Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN). Atherosclerosis Supplements, 2017, 29, 11-16.	1.2	53
59	Spectrum of mutations in Italian patients with familial hypercholesterolemia: New results from the LIPIGEN study. Atherosclerosis Supplements, 2017, 29, 17-24.	1.2	65
60	Atorvastatin but Not Pravastatin Impairs Mitochondrial Function in Human Pancreatic Islets and Rat \hat{I}^2 -Cells. Direct Effect of Oxidative Stress. Scientific Reports, 2017, 7, 11863.	1.6	59
61	HbA1c Identifies Subjects With Prediabetes and Subclinical Left Ventricular Diastolic Dysfunction. Journal of Clinical Endocrinology and Metabolism, 2017, 102, 3756-3764.	1.8	44
62	Screening for unknown hypercholesterolemia in a hospital population: A model for preventive medicine. Atherosclerosis, 2017, 263, e181.	0.4	0
63	High intake of dietary advanced glycation end-products is associated with increased arterial stiffness and inflammation in subjects with type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2017, 27, 978-984.	1.1	65
64	Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opinion on Pharmacotherapy, 2017, 18, 1243-1260.	0.9	35
65	Beneficial effect of lixisenatide after 76 weeks of treatment in patients with type 2 diabetes mellitus: A metaâ€analysis from the ⟨scp⟩ GetGoal⟨/scp⟩ programme. Diabetes, Obesity and Metabolism, 2017, 19, 248-256.	2.2	6
66	Cortisol as Biomarkers in Cirrhosis. Biomarkers in Disease, 2017, , 387-406.	0.0	0
67	Update on pre-diabetes: Focus on diagnostic criteria and cardiovascular risk. World Journal of Diabetes, 2016, 7, 423.	1.3	19
68	Low advanced glycation end product diet improves the lipid and inflammatory profiles of prediabetic subjects. Journal of Clinical Lipidology, 2016, 10, 1098-1108.	0.6	32
69	HbA1c increase is associated with higher coronary and peripheral atherosclerotic burden in non diabetic patients. Atherosclerosis, 2016, 255, 102-108.	0.4	54
70	Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. Internal and Emergency Medicine, 2016, 11, 905-916.	1.0	9
71	Altered expression of uncoupling protein 2 in GLP-1-producing cells after chronic high glucose exposure: implications for the pathogenesis of diabetes mellitus. American Journal of Physiology - Cell Physiology, 2016, 310, C558-C567.	2.1	22
72	Hepatic insulin resistance in NAFLD: relationship with markers of atherosclerosis and metabolic syndrome components. Acta Diabetologica, 2016, 53, 449-459.	1.2	14

#	Article	IF	CITATIONS
73	Low Endogenous Secretory Receptor for Advanced Glycation End-Products Levels Are Associated With Inflammation and Carotid Atherosclerosis in Prediabetes. Journal of Clinical Endocrinology and Metabolism, 2016, 101, 1701-1709.	1.8	40
74	Cortisol as Biomarkers in Cirrhosis. Biomarkers in Disease, 2016, , 1-20.	0.0	0
75	Hypothalamus-pituitary dysfunction is common in patients with stable cirrhosis and abnormal low dose synacthen test. Digestive and Liver Disease, 2015, 47, 1047-1051.	0.4	10
76	Apolipoprotein AI and HDL are reduced in stable cirrhotic patients with adrenal insufficiency: a possible role in glucocorticoid deficiency. Scandinavian Journal of Gastroenterology, 2015, 50, 347-354.	0.6	20
77	Diabetes increases renovascular impedance in patients with liver cirrhosis. Internal and Emergency Medicine, 2015, 10, 703-709.	1.0	2
78	Low circulating vitamin D levels are associated with increased arterial stiffness in prediabetic subjects identified according to HbA1c. Atherosclerosis, 2015, 243, 395-401.	0.4	26
79	Cardiovascular dysfunction in patients with liver cirrhosis. Annals of Gastroenterology, 2015, 28, 31-40.	0.4	70
80	Cardiovascular Risk Profile in Subjects With Prediabetes and New-Onset Type 2 Diabetes Identified by HbA1c According to American Diabetes Association Criteria. Diabetes Care, 2014, 37, 1447-1453.	4.3	57
81	CEBPA exerts a specific and biologically important proapoptotic role in pancreatic \hat{l}^2 cells through its downstream network targets. Molecular Biology of the Cell, 2014, 25, 2333-2341.	0.9	14
82	Lipid and liver abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Nutrition, Metabolism and Cardiovascular Diseases, 2014, 24, 670-676.	1.1	34
83	Comparison of Total Cortisol, Free Cortisol, and Surrogate Markers of Free Cortisol in Diagnosis of Adrenal Insufficiency in Patients With Stable Cirrhosis. Clinical Gastroenterology and Hepatology, 2014, 12, 504-512.e8.	2.4	45
84	Alpha- and beta-cell abnormalities in haemoglobin A1c-defined prediabetes and type 2 diabetes. Acta Diabetologica, 2014, 51, 567-575.	1.2	27
85	Chronic Exposure to GLP-1 Increases GLP-1 Synthesis and Release in a Pancreatic Alpha Cell Line (α-TC1): Evidence of a Direct Effect of GLP-1 on Pancreatic Alpha Cells. PLoS ONE, 2014, 9, e90093.	1.1	38
86	Beta and alpha cell function in metabolically healthy but obese subjects: Relationship with enteroâ€insular axis. Obesity, 2013, 21, 320-325.	1.5	27
87	Elevated plasma glucose-dependent insulinotropic polypeptide associates with hyperinsulinemia in metabolic syndrome. European Journal of Endocrinology, 2012, 166, 917-922.	1.9	25
88	Adrenocortical dysfunction in liver disease: A systematic review. Hepatology, 2012, 55, 1282-1291.	3.6	110
89	Corticosteroid replacement therapy in hepatoadrenal syndrome. European Journal of Gastroenterology and Hepatology, 2012, 24, 1.	0.8	3
90	Assessment of adrenocortical reserve in stable patients with cirrhosis. Journal of Hepatology, 2011, 54, 243-250.	1.8	75

#	Article	IF	CITATIONS
91	Palmitate Affects Insulin Receptor Phosphorylation and Intracellular Insulin Signal in a Pancreatic α-Cell Line. Endocrinology, 2010, 151, 4197-4206.	1.4	41
92	High insulin levels do not influence PC-1 gene expression and protein content in human muscle tissue and hepatoma cells. Diabetes/Metabolism Research and Reviews, 2000, 16, 26-32.	1.7	15
93	Exposure to glibenclamide increases rat beta cells sensitivity to glucose. British Journal of Pharmacology, 2000, 129, 887-892.	2.7	23
94	Reduction of advanced glycation end-product (AGE) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of poor metabolic control. European Journal of Neuroscience, 1998, 10, 2768-2775.	1.2	10
95	Chronic Exposure to High Glucose and Impairment of K+-Channel Function in Perifused Rat Pancreatic Islets. Diabetes, 1990, 39, 397-399.	0.3	22